Meet OraFyl™ at AAOMS 2026 in Seattle
BioCellgraft will be at the 2026 AAOMS Annual Meeting in Seattle. Here is a quick look at OraFyl™ and how to connect with our team while you are there.
PRODUCT SPOTLIGHT
Human placental connective tissue matrix (HPCTM) for clinician use in oral soft-tissue procedures. Available in flowable and particulate formulations.
WHAT IT IS
OraFyl™ is a human placental connective tissue matrix (HPCTM), a human cellular and tissue-based product regulated by the U.S. FDA under Section 361 of the Public Health Service Act and 21 CFR Part 1271.
It is intended to supplement or replace damaged or inadequate connective tissue in oral soft-tissue procedures, including soft-tissue voids, soft-tissue defects, and soft-tissue augmentation.
FORMATS
✓ Flowable
✓ Particulate
EXECUTIVE LEADERSHIP
Michel Dard, DDS, MS, PhD
Founder & Chief Executive Officer
Michael Wilhelm
Founder, Chairman & Chief Operating Officer
Charlie Vincent, MPH
Chief Commercial Officer
Hal Siegel, Ph.D.
Scientific Advisor and Regulatory Affairs Guidance
Lorenzo Tavelli, DDS, MS, PhD
Chief Clinical Officer
Shayan Barootchi, DMD, MS
Chief Science Officer
KEY OPINION LEADERS — EARLY ADOPTERS
Connect with the BioCellgraft team — share your contact details to request product information, pricing, or a conversation with the BioCellgraft team during AAOMS 2026.
YOUR CONTACT AT AAOMS
Charlie Vincent, MPH
Chief Commercial Officer
E-Mail - CVincent@biocellgraft.com
Office - 646-502-2201 ext. 106
Mobile - 214-864-2030
+Add to your contactsOraFyl™ is a trademark of BioCellgraft, Inc. — BioCellgraft, 212 Park Ave, New York, NY 10017, USA